Deutsche Bank AG Makes New $1.42 Million Investment in Artivion, Inc. $AORT

Key Points

• Deutsche Bank initiated a $1.42 million position in Artivion during the second quarter, purchasing 63,056 shares and owning approximately 0.13% of the company. Institutional investors collectively hold 86.37% of AORT.
• Artivion reported quarterly earnings of $0.13 per share and revenue of $125.76 million, exceeding analysts’ $119.99 million estimate. Shares opened at $26.77, well below their one-year high of $48.25.
• Analyst sentiment remains positive, with seven Buy ratings and one Sell rating and an average price target of $44.83, though insiders sold approximately $2.97 million of stock over the past 90 days.

Deutsche Bank AG bought a new position in Artivion, Inc. (NYSE:AORT - Free Report) in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 63,056 shares of the company's stock, valued at approximately $1,417,000. Deutsche Bank AG owned about 0.13% of Artivion at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of AORT. Vanguard Group Inc. lifted its position in Artivion by 4.7% in the fourth quarter. Vanguard Group Inc. now owns 3,170,089 shares of the company's stock valued at $144,588,000 after purchasing an additional 141,030 shares during the last quarter. Morgan Stanley increased its position in shares of Artivion by 0.8% in the fourth quarter. Morgan Stanley now owns 2,256,742 shares of the company's stock valued at $102,930,000 after acquiring an additional 18,248 shares during the period. State Street Corp boosted its holdings in shares of Artivion by 2.9% during the fourth quarter. State Street Corp now owns 1,584,920 shares of the company's stock worth $72,288,000 after purchasing an additional 44,641 shares during the period. Fred Alger Management LLC lifted its holdings in Artivion by 4.2% in the 4th quarter. Fred Alger Management LLC now owns 1,372,572 shares of the company's stock worth $62,603,000 after buying an additional 55,322 shares during the period. Finally, Conestoga Capital Advisors LLC bought a new stake in shares of Artivion in the 1st quarter worth approximately $43,044,000. Hedge funds and other institutional investors own 86.37% of the company's stock.

Artivion Stock Performance

Shares of AORT opened at $26.77 on Friday. The firm has a market capitalization of $1.31 billion, a P/E ratio of -382.37 and a beta of 1.25. The company has a debt-to-equity ratio of 0.82, a current ratio of 3.47 and a quick ratio of 2.51. Artivion, Inc. has a one year low of $19.16 and a one year high of $48.25. The business has a fifty day moving average of $25.64 and a 200 day moving average of $29.67.

Artivion (NYSE:AORT - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.13 earnings per share for the quarter. The business had revenue of $125.76 million for the quarter, compared to analysts' expectations of $119.99 million. Artivion had a negative net margin of 0.67% and a positive return on equity of 6.07%. As a group, sell-side analysts anticipate that Artivion, Inc. will post 0.45 EPS for the current year.

Insider Buying and Selling

In other news, CEO James P. Mackin sold 70,000 shares of the firm's stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $28.95, for a total transaction of $2,026,500.00. Following the completion of the transaction, the chief executive officer owned 877,275 shares in the company, valued at $25,397,111.25. This trade represents a 7.39% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Jean F. Holloway sold 977 shares of the stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $28.49, for a total value of $27,834.73. Following the transaction, the senior vice president owned 184,118 shares of the company's stock, valued at $5,245,521.82. This represents a 0.53% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 114,978 shares of company stock worth $2,965,155. 6.30% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

AORT has been the subject of several research reports. Wall Street Zen lowered Artivion from a "hold" rating to a "sell" rating in a research report on Saturday, August 15th. Stifel Nicolaus set a $45.00 price target on Artivion in a research note on Monday, June 1st. Needham & Company LLC reiterated a "buy" rating and issued a $44.00 price objective on shares of Artivion in a report on Monday, July 20th. Canaccord Genuity Group raised their price objective on Artivion from $39.00 to $40.00 and gave the company a "buy" rating in a research report on Tuesday, August 18th. Finally, Citigroup restated a "market outperform" rating on shares of Artivion in a report on Tuesday, July 21st. Seven research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, Artivion presently has an average rating of "Moderate Buy" and an average price target of $44.83.

About Artivion

Artivion, Inc NYSE: AORT is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.

Want to see what other hedge funds are holding AORT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Artivion, Inc. (NYSE:AORT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source